International consortium for personalized medicine: an international survey about the future of personalized medicine

Author:

Venne Julien12,Busshoff Ulrike3,Poschadel Sebastian4,Menschel Robin4,Evangelatos Nikolaos156,Vysyaraju Kranthi17,Brand Angela178

Affiliation:

1. UNU-MERIT (Maastricht Economic & Social Research Institute on Innovation & Technology), Maastricht University, 6211AX Maastricht, The Netherlands

2. Centre for Digital Health & Wellbeing (CDHW), Prasanna School of Public Health (PSPH), Manipal Academy of Higher Education, Manipal, Karnataka 576104, India

3. DLR Project Management Agency, 53227 Bonn, Germany and ICPerMed Secretariat

4. DLR Project Management Agency, Center of Expertise for Analysis and Evaluation, 53227 Bonn, Germany

5. Dr TMA Pai Endowment Chair in Research Policy in Biomedical Sciences & Public Health, Prasanna School of Public Health (PSPH), Manipal Academy of Higher Education, Manipal, Karnataka 576104, India

6. Intensive Care Medicine Unit, Department of Respiratory Medicine, Allergology & Sleep Medicine, Paracelsus Medical University (PMU), 90419 Nuremberg, Germany

7. Public Health Genomics, School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India

8. Department of International Health, Faculty of Health, Medicine & Life Sciences, Maastricht University, 6229 GT Maastricht, The Netherlands

Abstract

Aim: The ICPerMed, international initiative promoting personalized medicine, has realized a survey among a group of experts, to define a common vision for the deployment of personalized medicine across healthcare systems until 2030. Materials & methods: ICPerMed defined five perspectives (p.4) and addressed an online questionnaire to 97 international experts to collect their views. Results: Seventy (72%) of the 97 experts effectively answered the survey from which 69 answers were exploitable. Respondents from a variety of international profiles approved the five proposed perspectives and reported required actions and best practices. Conclusion: There is a large consensus among experts directly involved in shaping international strategies and policies, calling for voluntarist public policies, new IT platforms enabling data-driven approaches, large-scale educational programs and new financing models.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Molecular Medicine,General Medicine

Reference30 articles.

1. ICPerMed website. http://www.icpermed.eu

2. The Council of the European Union. European Council Conclusion on personalised medicine for patients, 2015/C 421/03 (citation from paragraph 8) (2015). https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:JOC_2015_421_R_0003&from=EN

3. ICPerMed. Members of ICPerMed. http://www.icpermed.eu/en/icpermed-members.php

4. European Commission. Use of ‘-omics’ technologies in the development of personalised medicine. https://ec.europa.eu/research/health/pdf/2013-10_personalised_medicine_en.pdf

5. European Commission. Staff working document on personalised medicine. http://ec.europa.eu/health/files/latest_news/2013-10_personalised_medicine_en.pdf

Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3